Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LipocineSTU:2VT0 47 3-Year EBITDA Growth Rate is 4.00% as of Jun. 2026, which is 75% below its 10-year median of 15.75. GuruFocus rates STU:2VT0 with a GF Score™ of 47/100 and a GF Value™ of €2.51. The stock has 4 warning signs investors should review. Among 1,131 Biotechnology companies, Lipocine ranks worse than 64.54% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 4.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 8.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 29.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Lipocine was 78.90% per year. The lowest was -121.70% per year. And the median was 15.75% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Lipocine 3-Year EBITDA Growth Rate Related Terms
STU:2VT0 vs NXTC, VYNE, QNCX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Lipocine's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipocine 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipocine's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Lipocine's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 4.00% mean?
Lipocine (STU:2VT0) has a 3-Year EBITDA Growth Rate of 4.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lipocine and its competitors. This is 75% below median its historical median of 15.75. According to the industry distribution chart, Lipocine ranks #730 out of 1131 companies in the Biotechnology industry, placing it in the top 64.5%.
Is Lipocine's 3-Year EBITDA Growth Rate too high?
Lipocine's current 3-Year EBITDA Growth Rate of 4.00% is 75% below median its 10-year median of 15.75. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Lipocine's value of 4.00% is 73.2% below this industry median. Based on the distribution chart, Lipocine ranks #730 out of 1131 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lipocine has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's 3-Year EBITDA Growth Rate compare to NXTC and VYNE?
According to the Biotechnology industry distribution chart, Lipocine ranks #730 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Lipocine in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Lipocine's value of 4.00% is 73.2% below this benchmark. While the company's 10-year median is 15.75 vs. the industry median of 14.90, Lipocine has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lipocine's current 3-Year EBITDA Growth Rate of 4.00% is 73.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lipocine and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipocine's current 3-Year EBITDA Growth Rate is 4.00%, which is 75% below median its own 10-year median of 15.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current 3-Year EBITDA Growth Rate of 4.00%. The stock's GF Value™ is €2.51, compared to a current price of €3.94 — trading 57.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 4.00%, which is 75% below median its 10-year median of 15.75 and 73.2% below the Biotechnology industry median of 14.90. Lipocine's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current 3-Year EBITDA Growth Rate is 4.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lipocine (STU:2VT0) Overvalued in 2026?
Based on GuruFocus' analysis, Lipocine stock appears to be overvalued.
The current stock price of €3.94 is trading 57.1% above its estimated GF Value™ of €2.51.
Key valuation signals for STU:2VT0:
3-Year EBITDA Growth Rate: 4.00% (75% below median its 10-year median of 15.75)
GF Value™: €2.51 vs. price of €3.94 (57.1% above fair value)
Industry Position: 73.2% below the Biotechnology median (#730 of 1131)
No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
47GF Score
Get the complete analysis for STU:2VT0
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2VT0 has been successfully added to your 
